<DOC>
	<DOCNO>NCT00268489</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving pemetrexed disodium together bevacizumab may effective treatment non-small cell lung cancer . PURPOSE : This phase II trial study well give pemetrexed disodium together bevacizumab work treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Disodium Bevacizumab Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess 3 month progression-free survival rate combination pemetrexed disodium bevacizumab patient population stage IIIB ( due pleural effusion ) IV non-small cell lung cancer . Secondary - Determine tumor response rate patient . - Determine effect pemetrexed disodium combination bevacizumab overall survival duration response patient . - Determine toxicity profile drug regimen patient . OUTLINE : This open-label , multicenter study . Patients receive pemetrexed disodium IV 10 minute bevacizumab IV 30-90 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically diagnose stage IIIB IV nonsmall cell lung cancer Stage IIIB patient must pleural effusion No symptomatic serosal effusion ( grade 2 dyspnea ) amenable drainage Mixed histology allow component consistent nonsmall cell lung cancer Tumors squamous cell histology feature allow Must measurable disease least one lesion long diameter accurately measure ≥ 2.0 cm conventional technique ≥ 1.0 cm spiral CT Large ( &gt; 4 cm ) centrally locate lesion large lesion close proximity major blood vessel receive palliative radiation The irradiated lesion target lesion Previously treat one chemotherapy regimen neoadjuvant , adjuvant , advanced disease set No symptomatic , untreated , uncontrolled CNS metastasis CNS metastasis treat prior whole brain radiotherapy allow PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/ mm^3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) direct bilirubin normal AST ALT ≤ 3 time ULN ( 5 time ULN liver tumor involvement ) Creatinine clearance ≥ 45 mL/min Urine protein : creatinine ratio &lt; 1.0 Pregnant nursing woman ineligible Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No seizure disorder No clinically significant infection No second primary malignancy within past 5 year except carcinoma situ cervix , nonmelanomatous skin cancer , lowgrade ( Gleason score ≤ 6 ) localize prostate cancer No hypertension labile hypertension No history poor compliance antihypertensive medication No angina pectoris No congestive heart failure within past 3 month unless ejection fraction &gt; 40 % No myocardial infarction within past 6 month No cardiac arrhythmia No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No active recent history hemoptysis Hemoptysis resolve &gt; 2 week ago measure palliative radiation therapy ( i.e. , 3,000 cGy 10 fraction ) , arteriographic embolization , endobronchial intervention ( e.g. , photodynamic therapy brachytherapy ) acceptable No diabetes No prior serious , nonhealing wound , ulcer , bone fracture No history stroke within past 6 month No history abdominal fistula gastrointestinal perforation No intraabdominal abscess within past 6 month Not great average risk bleed No significant traumatic injury within past 4 week PRIOR CONCURRENT THERAPY : No aspirin dose ≥ 1.3 gram per day within 10 day prior 10 day pemetrexed disodium treatment No chemotherapy within past 3 week ( 6 week mitomycin C nitrosoureas ) No immunotherapy biologic therapy within past 2 week No full field radiation therapy within past 4 week limited field radiation therapy within past 2 week The site previous radiotherapy evidence progressive disease site disease No prior post pelvic radiation No prior use pemetrexed disodium No prior radiation &gt; 25 % marrow cavity No major surgery ( i.e. , laparotomy ) open biopsy within past 4 week No minor surgery within past 2 week except insertion vascular access device No concurrent major surgery No chemotherapy , immunotherapy , hormonal therapy , radiotherapy , ancillary therapy consider investigational within past 4 week No concurrent use Hypericum perforatum ( St. John 's wort ) No concurrent anticoagulant use Lowdose warfarin heparin deep venous thrombosis prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>